Caribou Biosciences
Clinical-stage biopharmaceutical company developing genome-edited allogeneic (off-the-shelf) cell therapies. The organization focuses on next-generation CRISPR guide design that combines RNA and DNA components to improve editing specificity and enable multiplex, site-specific edits. Programs include allogeneic CAR-T and CAR-NK approaches engineered for immune evasion and enhanced activity, and clinical development includes Phase 1 studies in hematologic malignancies.
Industries
Nr. of Employees
medium (51-250)
Caribou Biosciences
Patents
Products
Allogeneic anti-CD19 CAR-T with PD-1 knockout (clinical-stage, Phase 1)
Donor-derived, genome-edited CAR-T therapy with TRAC disruption, site-specific CAR insertion into TRAC, and PD-1 knockout intended for relapsed/refractory B cell non-Hodgkin lymphoma; developed as an off-the-shelf product to reduce manufacturing timelines and enhance antitumor activity.
Allogeneic anti-BCMA CAR-T with immune cloaking (clinical-stage, Phase 1)
Donor-derived CAR-T therapy engineered with multiple edits including TRAC disruption, CAR insertion, and B2M knock-out with B2M–HLA-E fusion insertion to reduce host immune rejection by T and NK cells; developed for relapsed/refractory multiple myeloma.
Allogeneic anti-CLL-1 CAR-T for acute myeloid leukemia (early clinical)
Genome-edited donor-derived CAR-T therapy targeting CLL-1 being evaluated in early-stage clinical studies for relapsed/refractory acute myeloid leukemia.
iPSC-derived allogeneic CAR-NK cell therapy (preclinical)
Induced pluripotent stem cell (iPSC)-derived, engineered CAR-NK cell therapy designed for enhanced activity against solid tumors (preclinical data reported).
CB-011
CB-011 is a genome-edited allogeneic anti-B cell maturation antigen (BCMA) CAR-T cell product candidate engineered with next-generation CRISPR technology to knock out B2M and express a B2M-HLA-E fusion transgene for the treatment of relapsed or refractory multiple myeloma.
Vispa-cel
Vispacabtagene regedleucel (vispa-cel, formerly CB-010) is a lead clinical-stage allogeneic anti-CD19 CAR-T cell therapy utilizing a PD-1 knockout to limit premature CAR-T cell exhaustion for the treatment of relapsed or refractory B-NHL.
Allogeneic anti-CD19 CAR-T with PD-1 knockout (clinical-stage, Phase 1)
Donor-derived, genome-edited CAR-T therapy with TRAC disruption, site-specific CAR insertion into TRAC, and PD-1 knockout intended for relapsed/refractory B cell non-Hodgkin lymphoma; developed as an off-the-shelf product to reduce manufacturing timelines and enhance antitumor activity.
Allogeneic anti-BCMA CAR-T with immune cloaking (clinical-stage, Phase 1)
Donor-derived CAR-T therapy engineered with multiple edits including TRAC disruption, CAR insertion, and B2M knock-out with B2M–HLA-E fusion insertion to reduce host immune rejection by T and NK cells; developed for relapsed/refractory multiple myeloma.
Allogeneic anti-CLL-1 CAR-T for acute myeloid leukemia (early clinical)
Genome-edited donor-derived CAR-T therapy targeting CLL-1 being evaluated in early-stage clinical studies for relapsed/refractory acute myeloid leukemia.
iPSC-derived allogeneic CAR-NK cell therapy (preclinical)
Induced pluripotent stem cell (iPSC)-derived, engineered CAR-NK cell therapy designed for enhanced activity against solid tumors (preclinical data reported).
CB-011
CB-011 is a genome-edited allogeneic anti-B cell maturation antigen (BCMA) CAR-T cell product candidate engineered with next-generation CRISPR technology to knock out B2M and express a B2M-HLA-E fusion transgene for the treatment of relapsed or refractory multiple myeloma.
Vispa-cel
Vispacabtagene regedleucel (vispa-cel, formerly CB-010) is a lead clinical-stage allogeneic anti-CD19 CAR-T cell therapy utilizing a PD-1 knockout to limit premature CAR-T cell exhaustion for the treatment of relapsed or refractory B-NHL.
Expertise Areas
- Genome editing platform development
- Allogeneic cell therapy engineering
- Clinical trial management for early-stage cell therapies
- Immunoengineering and immune evasion strategies
Key Technologies
- Hybrid RNA–DNA CRISPR guides
- Cas12a-mediated genome editing
- Cas9-mediated genome editing
- Multiplex genome editing
News & Updates
Pre-publication draft describing Cas12a hybrid RNA-DNA-mediated in vivo genome editing for high-specificity functional gene disruption.
Presentation describing CB-011 with immune cloaking in patients with relapsed/refractory multiple myeloma presented at EHA 2026.
Presentation of Vispa-cel clinical results at EHA 2026.
Peer-reviewed article describing high-specificity CRISPR editing to suppress allograft rejection for anti-BCMA CAR-T in preclinical models.
Programs cited as having received or pursued Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations.
Pre-publication draft describing Cas12a hybrid RNA-DNA-mediated in vivo genome editing for high-specificity functional gene disruption.
Presentation describing CB-011 with immune cloaking in patients with relapsed/refractory multiple myeloma presented at EHA 2026.
Presentation of Vispa-cel clinical results at EHA 2026.
Peer-reviewed article describing high-specificity CRISPR editing to suppress allograft rejection for anti-BCMA CAR-T in preclinical models.
Programs cited as having received or pursued Regenerative Medicine Advanced Therapy (RMAT), Fast Track, and Orphan Drug designations.